Fidia S.p.A. (BIT:FDA)
0.0213
-0.0007 (-3.18%)
At close: Mar 20, 2026
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.02
Revenue / Employee
150.93K
Employees
140
Market Cap
317.37K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EuroGroup Laminations | 843.61M |
| Biesse | 662.48M |
| SIT S.p.A. | 314.71M |
| Tesmec | 257.61M |
| ILPRA | 80.39M |
| Clabo | 58.10M |
| OSAI Automation System | 41.92M |
| Marzocchi Pompe | 37.06M |
Fidia News
- 10 hours ago - Why Milestone Pharma Stock Is Taking A Dive Today - Benzinga
- 11 hours ago - Children's ibuprofen recall: FDA issues notice for Taro Pharmaceuticals' product - Associated Press
- 11 hours ago - Novo Nordisk Expands Obesity Drug Offerings with FDA Approval - GuruFocus
- 11 hours ago - Palatin's Case Strengthens as Rhythm's FDA Approval Validates Hypothalamic Obesity Market (PTN) - GuruFocus
- 12 hours ago - Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal - Nasdaq
- 12 hours ago - Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy - Benzinga
- 13 hours ago - Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' - Investor's Business Daily
- 15 hours ago - Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer - Benzinga